Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

Interim results from a Phase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly among bortezomib-naive patients. Of 14 evaluable bortezomib-naive patients, 57 percent achieved responses, including one patient with a complete response, two with very good partial responses and five with partial responses. Four additional patients achieved stable disease. Of 31 patients treated, 10 percent have received 12 cycles of treatment and have been enrolled in an extension study. Adverse events were generally mild and manageable. These data were presented by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation at Washington University School of Medicine in a poster titled "PX-171-004, a multicenter Phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update" (Abstract #8537).

Ruben Niesvizky, M.D., Associate Attending Physician, New York-Presbyterian Hospital and Associate Professor of Medicine at Weill Cornell Medical College presented preliminary data from an ongoing Phase 1b dose-escalating trial of carfilzomib in combination with lenalidomide and low-dose dexamethasone in relapsed and refractory patients. The combination of carfilzomib and lenalidomide is well tolerated and encouraging response rates have been observed. Of 18 evaluable patients, 61 percent have achieved partial or minor responses, including three very good partial responses. Notably, responses occurred in the first 28-day cycle of treatment and initial responses have improved with continued therapy. A maximum-tolerated dose has not yet been established and dose-escalation continues. These data were presented today in a poster titled "PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed and refractory mul
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 The National Space Biomedical ... Center for Space Radiation Research (CSRR) under the leadership ... an Associate Professor of Pharmaceutical Sciences within the University ... Division of Radiation Health. She is located in ... a team of investigators working across four U.S. institutions, ...
(Date:7/22/2014)... , July 22, 2014  Decision Resources Group finds that ... Canada will remain relatively stagnant at a value ... fact that percutaneous coronary intervention (PCI) volumes are growing faster ... markets, such as the United States ... largely driven by the increase in penetration of PCI procedures ...
(Date:7/22/2014)... July 22, 2014  Decision Resources Group finds ... (MS) patients currently treated with Biogen Idec,s ... experienced flushing and/or gastrointestinal events while on ... currently experiencing these side effects, signifying either ... management of such events. In the end, ...
Breaking Medicine Technology:Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3
... 14 New England Biolabs (NEB) has launched ... to simplify DNA methylation analysis for epigenetics researchers. ... of the current methods, including the lack of ... of 5-hydroxymethlcytosine (5-hmC) in the epigenome. ...
... Fe and Femcon® Fe... -- ARDEE, Ireland, Oct. 14 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome 2Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 2Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 3Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 4Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 5Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 6Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 7Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 8Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 9Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations 10
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
(Date:7/22/2014)... Robert E. Marc, Ph.D., director of research at the ... been named by the International Society of Eye Research ... Research Foundation,s 2014 Paul Kayser International Award in Retina ... scientist who has made a significant contribution to the ... being presented this week at the ISER Biennial Meeting ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
(Date:7/22/2014)... Latin American Conference on Lung Cancer (LALCA 2014) will ... Peru. , Lung Cancer is still the leading cause ... Building on the success of the previous conferences in ... will discuss the science and advances in the treatment ... and Latin America in particular. , With tobacco being ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... human body, HOUSTON, Sept. 25 Can you ... Simply visit The John P. McGovern Museum of Health ... explore the latest,exhibit -- Sesame Street Presents: The Body ... October 4, 2007 and January 13, 2008.,The exhibit offers ...
... 25 A Place for Mom, the nation,s largest,referral ... that John,Temple, Chief Operating Officer was named to the ... The 40 Under 40 List is the Pacific Northwest ... They look for,nominees that work hard to drive the ...
... Phase II data presented today suggest that ZD4054, a ... with Hormone Resistant Prostate Cancer (HRPC), could offer a ... HRPC who were asymptomatic or mildly symptomatic for pain.1 ... percent reduction in the risk of death compared to ...
... 25 ThermoSpas, the country,s,largest hot tub retailer, ... chronically,ill children to give specially-designed therapeutic hot tubs ... program, the company will donate 12,ThermoSpas hot tubs ... who will benefit,from warm water therapy. ThermoSpas encourages ...
... Continuum Health Partners Selects Ericom(R) PowerTerm(R) WebConnect for ... ... 25 Continuum Health Partners, a,New York-based non-profit hospital system, ... of Continuum,s strategy to,provide doctors and staff with secure, on-demand ...
... youngsters to stay healthy, , , TUEDAY, Sept. 25 (HealthDay News) ... and way too much junk food are pushing U.S. children ... new studies finds. , The studies -- published in a ... -- show the myriad challenges youngsters face every day ...
Cached Medicine News:Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 2Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 3Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 4Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 5Health News:Sesame Street Exhibition Makes Texas Premier at The Health Museum 6Health News:A Place for Mom COO Makes Seattle's 40 Under 40 List 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 2Health News:Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054 3Health News:Photos: America's Chronically Ill Children Have New Hope with 'Hot' Gift 2Health News:Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization 2Health News:Junk Food, TV Driving Kids to Obesity 2Health News:Junk Food, TV Driving Kids to Obesity 3Health News:Junk Food, TV Driving Kids to Obesity 4
... The CKX microscopes utilize the ... visibility and operability in cell ... cost-effective inverted microscope suited to ... of fields--from tissue culture and ...
Continuous rocking motion graphic display....
Stainless steel lockable wall display for up to 12 frames....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: